Close Menu

Precision Oncology Reimbursement News

Reimbursement news and insurance coverage updates.

Colorectal Cancer Canada, which led the survey, will share the data with decisionmakers, hoping to increase understanding of access barriers and change health policy.  

The final decision includes some changes, most notably removing requirements for guideline inclusion, but retains its technical performance benchmarks.

Verzenio, Ibrance, Rubraca, and bintrafusp alfa are some of the precision oncology products companies provided updates on during the conference.